Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Email: |
info@bocsci.com |
Products Intro: |
Product Name:galacto-Dapagliflozin CAS:1408245-02-2 Purity:95% Package:1G;10G;100G Remarks:Galacto-Dapagliflozin potently inhibits human SGLT2 (Ki = 2 nM) which is 1,000-fold less potent at human SGLT1 (Ki = 25,000).
|
Company Name: |
Hubei Xinyang Medical Technology Co., Ltd
|
Tel: |
15347293736 15347293736 |
Email: |
2853117764@qq.com |
Products Intro: |
Product Name:Dapagliflozin Impurity 43 CAS:1408245-02-2 Purity:99% HPLC Package:10mg;25mg;50mg;100mg;200mg;500mg
|
Company Name: |
MedBioPharmaceutical Technology Inc
|
Tel: |
021-69568360 18916172912 |
Email: |
order@med-bio.cn |
Products Intro: |
Product Name:galacto-Dapagliflozin CAS:1408245-02-2 Purity:98% Package:10mg; 50mg; 1mg; 5mg Remarks:Medbio
|
Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
Tel: |
021-65675885 18964387627 |
Email: |
customer_service@efebio.com |
Products Intro: |
Product Name:galacto-Dapagliflozin CAS:1408245-02-2 Purity:95% Package:1mg;5mg;10mg
|
Company Name: |
ApexBio Technology
|
Tel: |
+ 1-832-696-8203 |
Email: |
sales@apexbt.com |
Products Intro: |
Product Name:galacto-Dapagliflozin CAS:1408245-02-2
|
|
| galacto-Dapagliflozin Basic information |
Product Name: | galacto-Dapagliflozin | Synonyms: | galacto-Dapagliflozin;JVHXJTBJCFBINQ-IFLJBQAJSA-N;D-Galactitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-;Dapagliflozin Galacto Isomer;(1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-galactitol | CAS: | 1408245-02-2 | MF: | C21H25ClO6 | MW: | 408.87 | EINECS: | | Product Categories: | | Mol File: | 1408245-02-2.mol | ![galacto-Dapagliflozin Structure](CAS/20181012/GIF/1408245-02-2.gif) |
| galacto-Dapagliflozin Chemical Properties |
storage temp. | Store at -20°C | solubility | ≤30mg/ml in DMSO;50mg/ml in dimethyl formamide | form | crystalline solid |
| galacto-Dapagliflozin Usage And Synthesis |
Biological Activity | ki = 2 nmgalacto-dapagliflozin is a potent inhibitor of human sglt2.renal glucose transport is mediated by sodium-glucose cotransporters (sglt) 1 and 2. in humans, sglt2 is responsible for the majority of glucose reabsorption in the kidney. | in vitro | it was found that galacto-dapagliflozin was a selective inhibitor of hsglt2, but was less potent than dapagliflozin for both transporters. both phlorizin and galacto-dapagliflozin rapidly dissociated from sglt2, while dapagliflozin and fluoro-dapagliflozin dissociated from hsglt2 at a rate 10-fold slower. dapagliflozin, fluoro-dapagliflozin, and galacto-dapagliflozin dissociated quickly from hsglt1, and phlorizin readily exchanged with dapagliflozin bound to hsglt1 [1]. | in vivo | male db/db mice were administered dapagliflozin for 12 weeks. results showed that administration of dapagliflozin could ameliorate hyperglycemia, β-cell damage and albuminuria in db/db mice. serum creatinine, creatinine clearance and blood pressure were not affected by administration of dapagliflozin. dapagliflozin treatment was able to decrease macrophage infiltration in the kidney of db/db mice [2]. | references | [1] hummel, c. s.,lu, c.,liu, j., et al. structural selectivity of human sglt inhibitors. american journal of physiology.cell physiology 302(2), c373-c382 (2012). [2] terami n et al. long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. plos one. 2014 jun 24;9(6):e100777. [3] merovci a et al. dapagliflozin lowers plasma glucose concentration and improves β-cell function. j clin endocrinol metab. 2015 may;100(5):1927-32. |
| galacto-Dapagliflozin Preparation Products And Raw materials |
|